Literature DB >> 33434685

Monoamine oxidases in age-associated diseases: New perspectives for old enzymes.

Yohan Santin1, Jessica Resta1, Angelo Parini1, Jeanne Mialet-Perez2.   

Abstract

Population aging is one of the most significant social changes of the twenty-first century. This increase in longevity is associated with a higher prevalence of chronic diseases, further rising healthcare costs. At the molecular level, cellular senescence has been identified as a major process in age-associated diseases, as accumulation of senescent cells with aging leads to progressive organ dysfunction. Of particular importance, mitochondrial oxidative stress and consequent organelle alterations have been pointed out as key players in the aging process, by both inducing and maintaining cellular senescence. Monoamine oxidases (MAOs), a class of enzymes that catalyze the degradation of catecholamines and biogenic amines, have been increasingly recognized as major producers of mitochondrial ROS. Although well-known in the brain, evidence showing that MAOs are also expressed in a variety of peripheral organs stimulated a growing interest in the extra-cerebral roles of these enzymes. Besides, the fact that MAO-A and/or MAO-B are frequently upregulated in aged or dysfunctional organs has uncovered new perspectives on their roles in pathological aging. In this review, we will give an overview of the major results on the regulation and function of MAOs in aging and age-related diseases, paying a special attention to the mechanisms linked to the increased degradation of MAO substrates or related to MAO-dependent ROS formation.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Age-associated chronic diseases; Autophagy; Mitochondria; Monoamine oxidases; ROS; Senescence

Year:  2021        PMID: 33434685     DOI: 10.1016/j.arr.2021.101256

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  7 in total

1.  Dual monoamine oxidase B and acetylcholine esterase inhibitors for treating movement and cognition deficits in a C. elegans model of Parkinson's disease.

Authors:  Jacob Boos; Ahmed Shubbar; Werner J Geldenhuys
Journal:  Med Chem Res       Date:  2021-04-09       Impact factor: 2.351

2.  Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer.

Authors:  Sanaa Bardaweel; Reem Aljanabi; Dima Sabbah; Kamal Sweidan
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

Review 3.  Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.

Authors:  Reem Aljanabi; Lina Alsous; Dima A Sabbah; Halise Inci Gul; Mustafa Gul; Sanaa K Bardaweel
Journal:  Molecules       Date:  2021-10-04       Impact factor: 4.411

4.  COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes.

Authors:  Lucija Hok; Hrvoje Rimac; Janez Mavri; Robert Vianello
Journal:  Comput Struct Biotechnol J       Date:  2022-02-24       Impact factor: 7.271

5.  Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versus trans-6-Styrylcoumarin.

Authors:  Marco Mellado; César González; Jaime Mella; Luis F Aguilar; Ismail Celik; Fernanda Borges; Eugenio Uriarte; Giovanna Delogu; Dolores Viña; Maria J Matos
Journal:  Molecules       Date:  2022-01-29       Impact factor: 4.411

6.  Monoamine Oxidase Inhibitors Prevent Glucose-Dependent Energy Production, Proliferation and Migration of Bladder Carcinoma Cells.

Authors:  Jessica Resta; Yohan Santin; Mathieu Roumiguié; Elodie Riant; Alexandre Lucas; Bettina Couderc; Claudia Binda; Philippe Lluel; Angelo Parini; Jeanne Mialet-Perez
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

Review 7.  Procaine-The Controversial Geroprotector Candidate: New Insights Regarding Its Molecular and Cellular Effects.

Authors:  Daniela Gradinaru; Anca Ungurianu; Denisa Margina; Maria Moreno-Villanueva; Alexander Bürkle
Journal:  Oxid Med Cell Longev       Date:  2021-07-31       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.